AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2923425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (regulated and unregulated)
Number of subjects: 90
Study 2923425 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who underwent gastric or duodenal procedures (n = 14)
Number of subjects: 90
Study 29698720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine dripped onto the skin prior to injection (1-2 ml)
Number of subjects: 481
Study 29698720 — intervention group
Group type: COMPARATOR
Intervention: Control group (1% subcutaneous lidocaine injection without prior skin application)
Number of subjects: 481
Study 29698720 — intervention group
Group type: COMPARATOR
Intervention: Control group for peripherally inserted central catheters (1% subcutaneous lidocaine injection without prior skin application)
Number of subjects: 481
Study 26812508 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intake
Number of subjects: 3076
Study 26812508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy consumption (excess vs adequate) among women
Number of subjects: 3076
Study 25463092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba treatment for 2 months
Number of subjects: 11
Study 22515587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglow®
Number of subjects: 40
Study 22515587 — intervention group
Group type: EXPERIMENTAL
Intervention: IAL System®
Number of subjects: 40
Study 20190354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecklonia cava polyphenol (ECP) supplementation
Number of subjects: 20
Study 20190354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18614926 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Interruption (TI)
Number of subjects: 37
Study 18614926 — intervention group
Group type: COMPARATOR
Intervention: Highly Active Antiretroviral Therapy (HAART)
Number of subjects: 37
Study 16078326 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal interview
Number of subjects: 119
Study 16078326 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 119
Study 16078326 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed questionnaire
Number of subjects: 119
Study 11980742 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation (2 mg midazolam and 25 microg fentanyl) i.v. 5 min before cervical dilatation
Number of subjects: 100
Study 11980742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 10895158 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (single-agent) in second-line NSCLC
Number of subjects: 0
Study 10895158 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (single-agent) in first-line NSCLC
Number of subjects: 0
Study 10895158 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (Phase III randomized study)
Number of subjects: 0
Study 10895158 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (Phase III studies)
Number of subjects: 0
Study 8828420 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic salpingostomy
Number of subjects: 48
Study 8828420 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic local methotrexate injection
Number of subjects: 48
Study 1592955 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT (Child Management Training)
Number of subjects: 22
Study 1592955 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT plus AST (Adjunctive Ally Support Training)
Number of subjects: 22
Study 1592955 — intervention group
Group type: COMPARATOR
Intervention: CMT or CMT plus AST
Number of subjects: 22
Study 6706437 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16
Study 6706437 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 16
Study 30678333 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg·kg−1)
Number of subjects: 24
Study 30678333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 24
Study 30126153 — intervention group
Group type: EXPERIMENTAL
Intervention: InferrinTM (microencapsulated bovine lactoferrin) 200 mg
Number of subjects: 12
Study 30126153 — intervention group
Group type: EXPERIMENTAL
Intervention: InferrinTM (microencapsulated bovine lactoferrin) 600 mg
Number of subjects: 12
Study 30126153 — intervention group
Group type: COMPARATOR
Intervention: Standard bovine lactoferrin
Number of subjects: 12
Study 30126153 — intervention group
Group type: EXPERIMENTAL
Intervention: InferrinTM (microencapsulated bovine lactoferrin)
Number of subjects: 12
Study 30126153 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 12
Study 26787572 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 40
Study 26787572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25424810 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study 25424810 — intervention group
Group type: EXPERIMENTAL
Intervention: rMenB with reduced OMV doses (0, ¼ or ½ the OMV dose)
Number of subjects: 0
Study 25424810 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose of 4CMenB
Number of subjects: 0
Study 25424810 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelicensure formulation of 4CMenB
Number of subjects: 0
Study 25424810 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB (4-dose primary/booster series)
Number of subjects: 0
Study 22637202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle distraction permitting joint motion
Number of subjects: 36
Study 22637202 — intervention group
Group type: COMPARATOR
Intervention: Fixed ankle distraction
Number of subjects: 36
Study 20214820 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety symptoms measured by the Spielberger State Trait Anxiety Inventory (STAI)
Number of subjects: 1828
Study 17050578 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops, twice-daily for 3 days
Number of subjects: 1043
Study 17050578 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3%, 1 drop every two hours for 2 days, then four times daily for 5 days
Number of subjects: 1043
Study 17050578 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops
Number of subjects: 1043
Study 15960286 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone (n=13)
Number of subjects: 26
Study 15960286 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (n=13)
Number of subjects: 26
Study 11382537 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) consisting of 30 trains of 2‐s duration stimuli (20 Hz, 90% of motor threshold), after 10 daily sessions.
Number of subjects: 7
Study 11382537 — intervention group
Group type: COMPARATOR
Intervention: Placebo conditions (sham-rTMS) with identical design but addressing coil discharges to the air.
Number of subjects: 7
Study 11382537 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 7
Study 9264868 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol (50 micrograms transdermally or 2 mg orally)
Number of subjects: 72
Study 9264868 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin (200 IU every other day)
Number of subjects: 72
Study 8353409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 40 micrograms twice daily
Number of subjects: 61
Study 8353409 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol 20 micrograms four times daily
Number of subjects: 61
Study 8353409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with at least 3 adverse reactions
Number of subjects: 61
Study 8353409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with one or two adverse reactions
Number of subjects: 61
Study 8353409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with nausea and vomiting
Number of subjects: 61
Study 8353409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without nausea and vomiting
Number of subjects: 61
Study 8353409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate or severe side effects
Number of subjects: 61
Study 8353409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild side effects
Number of subjects: 61
Study 2892452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 60
Study 2892452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 60
Study 2892452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 60
Study 2892452 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 60
Study 2892452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2676348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high-frequency ventilation (CHFV)
Number of subjects: 35
Study 2676348 — intervention group
Group type: COMPARATOR
Intervention: Controlled mechanical ventilation (CMV)
Number of subjects: 35
Study 31463686 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 trial facilitated by a mobile health app
Number of subjects: 215
Study 31238121 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 780
Study 31238121 — intervention group
Group type: COMPARATOR
Intervention: Iodine-alcohol
Number of subjects: 780
Study 28283779 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-344 10 mg/kg intravenously weekly plus topotecan 4 mg/m2 on days 1, 8, and 15 of a 28 day cycle
Number of subjects: 46
Study 26003334 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet for 4 months
Number of subjects: 20
Study 26003334 — intervention group
Group type: COMPARATOR
Intervention: Traditional heart-healthy diet for 4 months
Number of subjects: 20
Study 23001292 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 20 μg/kg
Number of subjects: 54
Study 23001292 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 0.5 mg/kg
Number of subjects: 54
Study 22073899 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 0
Study 22073899 — intervention group
Group type: COMPARATOR
Intervention: Behavioral modifications
Number of subjects: 0
Study 19893466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite with the adjunct of a proteolytic enzyme
Number of subjects: 200
Study 19893466 — intervention group
Group type: COMPARATOR
Intervention: Standard sodium hypochlorite
Number of subjects: 200
Study 16402229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily calcium hydroxide suspension (Osteoinductal) applied subgingivally after nonsurgical periodontal therapy
Number of subjects: 19
Study 14766981 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttrial infusion of 0.75 mg of the cholinesterase inhibitor physostigmine
Number of subjects: 0
Study 14766981 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 11378598 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilational tracheostomy (PDT)
Number of subjects: 80
Study 9234039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (25 mg i.v.) administered on 2 days
Number of subjects: 8
Study 9234039 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 ml i.v.) administered on 1 day
Number of subjects: 8
Study 8122716 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid, 1 percent
Number of subjects: 117
Study 8122716 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid, 1.9 percent
Number of subjects: 117
Study 8122716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hyaluronic acid)
Number of subjects: 117
Study 2441374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-responsive pacing (60/125-150 bpm)
Number of subjects: 15
Study 2441374 — intervention group
Group type: COMPARATOR
Intervention: Fixed rate ventricular pacing (70 bpm)
Number of subjects: 15
Study 2441374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-responsive pacing
Number of subjects: 15
Study 28990126 — intervention group
Group type: EXPERIMENTAL
Intervention: T-PRF
Number of subjects: 114
Study 28990126 — intervention group
Group type: COMPARATOR
Intervention: CTG
Number of subjects: 114
Study 28974567 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment mean systolic blood pressure (SBP)
Number of subjects: 28790
Study 28974567 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit systolic blood pressure variability (SBP-CV)
Number of subjects: 28790
Study 28974567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of on-treatment mean SBP and SBP-CV
Number of subjects: 28790
Study 26288199 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (25/125 mcg) through BAI
Number of subjects: 150
Study 26288199 — intervention group
Group type: COMPARATOR
Intervention: SFC (25/125 mcg) through pMDI
Number of subjects: 150
Study 26288199 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (25/125 mcg) through BAI and pMDI
Number of subjects: 150
Study 26288199 — intervention group
Group type: EXPERIMENTAL
Intervention: BAI device
Number of subjects: 150
Study 26288199 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC in both BAI and pMDI
Number of subjects: 150
Study 23972966 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50mg
Number of subjects: 26
Study 23972966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21288053 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of current PPI treatment
Number of subjects: 0
Study 21288053 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (more effective acid inhibitor)
Number of subjects: 0
Study 21288053 — intervention group
Group type: COMPARATOR
Intervention: Standard PPI treatment (control)
Number of subjects: 0
Study 19776456 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft home care services and an offer of social caretaking
Number of subjects: 2612
Study 19776456 — intervention group
Group type: COMPARATOR
Intervention: Only soft home care
Number of subjects: 2612
Study 16508577 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 116
Study 16508577 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 116
Study 15285457 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ electrodermal diagnostics (OED)
Number of subjects: 200
Study 11584993 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B with or without flucytosine
Number of subjects: 0
Study 11584993 — intervention group
Group type: EXPERIMENTAL
Intervention: Azoles and other formulations of amphotericin B
Number of subjects: 0
Study 9227167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydroxychloroquine (HCQ)
Number of subjects: 100
Study 9227167 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular gold
Number of subjects: 100
Study 9227167 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 8115343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline condition
Number of subjects: 0
Study 8115343 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 8115343 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva thiocyanate measure
Number of subjects: 0
Study 3117402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of adriamycin (20 mg/40 ml or 30 mg/30 ml)
Number of subjects: 130
Study 3117402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of mitomycin C (20 mg/40 ml)
Number of subjects: 130
Study 3117402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of thio-TEPA (30 mg/30 ml)
Number of subjects: 130
Study 3117402 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninstillation treatments with etretinate or tegafur
Number of subjects: 130
Study 3117402 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 3117402 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 or grade 2 disease treated with prophylactic instillation
Number of subjects: 130
Study 31356704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for PTSD
Number of subjects: 90
Study 29068297 — intervention group
Group type: EXPERIMENTAL
Intervention: Care-management approach (Group 1)
Number of subjects: 10
Study 29068297 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach (Group 2)
Number of subjects: 10
Study 25683060 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurokinin B (NKB) administration
Number of subjects: 10
Study 25683060 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) infusion
Number of subjects: 10
Study 23650890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programme for morphosyntactic skills
Number of subjects: 20
Study 23650890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 21460066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage Autograft Implantation System (CAIS)
Number of subjects: 29
Study 21460066 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MFX)
Number of subjects: 29
Study 18641093 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan-guided bronchoscopy
Number of subjects: 50
Study 18641093 — intervention group
Group type: COMPARATOR
Intervention: Conventional bronchoscopy
Number of subjects: 50
Study 16920776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (114 players)
Number of subjects: 723
Study 16920776 — intervention group
Group type: COMPARATOR
Intervention: Control group (609 players)
Number of subjects: 723
Study 12895165 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 50 mg
Number of subjects: 60
Study 12895165 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg
Number of subjects: 60
Study 12895165 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 60
Study 12895165 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 162.5 mg
Number of subjects: 60
Study 12895165 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 60
Study 12895165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coronary artery disease)
Number of subjects: 60
Study 10718778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban
Number of subjects: 38
Study 10718778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine/Aspirin
Number of subjects: 38
Study 10718778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban/Ticlopidine/Aspirin
Number of subjects: 38
Study 8824104 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based instruction
Number of subjects: 34
Study 8824104 — intervention group
Group type: COMPARATOR
Intervention: Personal instruction (Control)
Number of subjects: 34
Study 1467104 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 500
Study 1467104 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 500
Study 6748068 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 189
Study 6748068 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed use of calendars with sticker reminders
Number of subjects: 189
Study 6748068 — intervention group
Group type: COMPARATOR
Intervention: Non-cyclic women
Number of subjects: 189
Study 31584222 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 35
Study 30293295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg carboprost methylate suppository
Number of subjects: 1614
Study 25642882 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm plastic bag application
Number of subjects: 0
Study 25642882 — intervention group
Group type: COMPARATOR
Intervention: Control (no warm bag application)
Number of subjects: 0
Study 23782001 — intervention group
Group type: EXPERIMENTAL
Intervention: vitamins and minerals (vit&min) treatment (group A; N.274)
Number of subjects: 552
Study 23782001 — intervention group
Group type: COMPARATOR
Intervention: calcium/vitamin D3 treatment (group B; N.278)
Number of subjects: 552
Study 21832831 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with birch extract
Number of subjects: 40
Study 21832831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with birch extract
Number of subjects: 40
Study 19737029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold conditions (ambient temperature: 5 +/- 1 degrees C, relative humidity 41% +/- 9%)
Number of subjects: 22
Study 19737029 — intervention group
Group type: COMPARATOR
Intervention: Room temperature conditions (ambient temperature: 21 +/- 1 degrees C, relative humidity 35% +/- 5%)
Number of subjects: 22
Study 17576867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg BID
Number of subjects: 418
Study 17576867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg BID
Number of subjects: 418
Study 17576867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg BID
Number of subjects: 418
Study 17576867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg once daily
Number of subjects: 418
Study 17576867 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/vitamin K antagonist
Number of subjects: 418
Study 14991935 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g twice daily for 1 week (Group I)
Number of subjects: 164
Study 14991935 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g twice daily for 2 weeks (Group II)
Number of subjects: 164
Study 14991935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsitrate 300 mg, tetracyline 500 mg, metronidazole 500 mg four times daily in addition to Omeprazole 20 mg twice daily (Group III)
Number of subjects: 164
Study 11458720 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg b.w.)
Number of subjects: 10
Study 11458720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11458720 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (for treatment of severe agitation)
Number of subjects: 10
Study 9715356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-alcohol (4 doses of intranasal cocaine 1 mg/kg every 30 min with oral alcohol 1 g/kg)
Number of subjects: 0